title: Low dose aspirin and cognitive function in the women's health study cognitive cohort.
abstract: OBJECTIVE
  To determine whether low dose aspirin protects women aged 65 or more against cognitive decline.
  
  
  METHODS
  Cohort study within both arms of the women's health study, a randomised, double blind, placebo controlled trial of low dose aspirin for the primary prevention of cardiovascular disease and cancer, 1992-5.
  
  
  METHODS
  Women's health study, 1998-2004.
  
  
  METHODS
  6377 women aged 65 or more.
  
  
  METHODS
  Low dose aspirin (100 mg on alternate days) or placebo for a mean of 9.6 years.
  
  
  METHODS
  Women had three cognitive assessments at two year intervals by telephone. The battery to assess cognition included five tests measuring general cognition, verbal memory, and category fluency. The primary prespecified outcome was a global score, averaging performance across all tests. The key secondary outcome was a verbal memory score, averaging performance on four measures of verbal memory.
  
  
  RESULTS
  At the initial assessment (mean 5.6 years after randomisation) cognitive performance in the aspirin group was similar to that of the placebo group (mean difference in global score -0.01, 95% confidence interval -0.04 to 0.02). Mean decline in the global score from the first to the final cognitive assessment was also similar in the aspirin compared with placebo groups (mean difference 0.01, -0.02 to 0.04). The risk of substantial decline (in the worst 10th centile of decline) was also comparable between the groups (relative risk 0.92, 0.77 to 1.10). Findings were similar for verbal memory; however, a 20% lower risk was observed for decline in category fluency with aspirin (relative risk 0.80, 0.67 to 0.97).
  
  
  CONCLUSIONS
  Long term use of low dose aspirin does not provide overall benefits for cognition among generally healthy women aged 65 or more.
authors.affiliation: Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. nhjhk@channing.harvard.edu
authors.forename: Jae Hee
authors.initials: JH
authors.lastname: Kang
authors.forename: Nancy
authors.initials: N
authors.lastname: Cook
authors.forename: JoAnn
authors.initials: J
authors.lastname: Manson
authors.forename: Julie E
authors.initials: JE
authors.lastname: Buring
authors.forename: Francine
authors.initials: F
authors.lastname: Grodstein
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000517:prevention & control* / Q000523:psychology; D003072:Cognition Disorders / Q000517:prevention & control* / Q000523:psychology; D015331:Cohort Studies; D006304:Health Status; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000175:diagnosis / Q000517:prevention & control; D018697:Nootropic Agents / Q000008:administration & dosage*; D011581:Psychological Tests; D016896:Treatment Outcome
chemical_list: D018697:Nootropic Agents; D001241:Aspirin